Pfizer INC Form 4 insider transactions

NYSE
Christoffel Boshoff, President of R&D at Pfizer, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
NYSE
Pfizer's CEO, Albert Bourla, reported the acquisition of 75 phantom stock units through the Pfizer Supplemental Savings Plan on January 13, 2025.
NYSE
Pfizer director James C. Smith acquired 1,696.193 phantom stock units as part of deferred compensation.
NYSE
Pfizer director Cyrus Taraporevala acquired 1,413.494 phantom stock units as part of deferred compensation.
NYSE
Rady A. Johnson, Executive Vice President of Pfizer Inc., reports changes in beneficial ownership due to the acquisition of phantom stock units under the company's Supplemental Savings Plan.
NYSE
Pfizer director James Quincey acquired 1,460.611 phantom stock units as part of deferred compensation, which will be settled in cash or common stock upon retirement.
NYSE
Pfizer director Shantanu Narayen acquired 1,884.659 phantom stock units as part of deferred compensation, which will be settled in cash or common stock upon retirement.
NYSE
Pfizer director Joseph Echevarria acquired 1,743.309 phantom stock units representing deferred compensation.
NYSE
Pfizer's CEO, Albert Bourla, acquired 20 phantom stock units through the company's Supplemental Savings Plan.
NYSE
Pfizer's CEO, Albert Bourla, acquired 21 phantom stock units through the company's Supplemental Savings Plan, as detailed in a recent SEC filing.
NYSE
Pfizer's Executive Vice President, Rady A. Johnson, acquired 7 phantom stock units through the company's Supplemental Savings Plan.
NYSE
Pfizer's Executive Vice President, Rady A. Johnson, acquired 7 phantom stock units through the company's Supplemental Savings Plan.
NYSE
Pfizer's CEO, Albert Bourla, acquired 20 phantom stock units through the company's Supplemental Savings Plan.
NYSE
Pfizer's Executive Vice President, Rady A. Johnson, acquired 8 phantom stock units through the company's Supplemental Savings Plan.
NYSE
Pfizer's CEO, Albert Bourla, acquired 21 phantom stock units through the company's Supplemental Savings Plan, as reported in a recent SEC filing.
NYSE
Executive Vice President Rady A. Johnson reports acquiring phantom stock units in Pfizer through the Supplemental Savings Plan.
NYSE
Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of phantom stock units through the company's Supplemental Savings Plan.
NYSE
Director Scott Gottlieb reported purchasing 1,000 shares of Pfizer stock at $28.24 on October 30, 2024.
NYSE
Executive Vice President Rady A. Johnson reports acquiring phantom stock units in Pfizer through the Supplemental Savings Plan.
NYSE
Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 18 phantom stock units through the company's Supplemental Savings Plan.
NYSE
Director Mortimer J. Buckley acquired 3,771.092 phantom stock units of Pfizer Inc. as deferred compensation under the company's Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
NYSE
Executive Vice President Rady A. Johnson reports acquiring phantom stock units in Pfizer through the Supplemental Savings Plan.
NYSE
Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 69 phantom stock units through the company's Supplemental Savings Plan.
NYSE
Director Cyrus Taraporevala reports acquisition of phantom stock units representing deferred director's compensation.
NYSE
Director James C. Smith reported the acquisition of phantom stock units representing deferred director's compensation.
NYSE
Director James Quincey reports acquiring phantom stock units representing deferred director's compensation in Pfizer Inc.
NYSE
Director Shantanu Narayen reports acquisition of phantom stock units in Pfizer, reflecting deferred compensation.
NYSE
Director Joseph Echevarria reports acquisition of phantom stock units representing deferred director's compensation in a recent SEC filing.
NYSE
Executive Vice President Rady A. Johnson reports the acquisition of phantom stock units in Pfizer through the company's Supplemental Savings Plan.
NYSE
Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of phantom stock units through the company's Supplemental Savings Plan.